ArticleFrontiers in pharmacology2026

Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China.

Mengmeng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.